Right now, you have a unique opportunity to influence Congress about the need to increase NIH research on understanding chronic pain and opioids that could lead to new treatments. In 2016, The Alliance for Headache Disorders Advocacy (AHDA), helped to have provisions focused on increasing NIH pain research included in the Comprehensive Addiction and Recovery Act (CARA). CARA was signed into law in July 2016. Since then, the AHDA has been collaborating on a bill to fully fund these provisions. That bill was recently introduced:
You can help pass this bill by urging your Members of Congress to co-sponsor it now.
Please click on the link below to send emails to your Members of Congress.
Space is provided where you can add a concise description (3 sentences, tops) of why this issue and this research is so important to you.
Please do not make any edits (additions or deletions) to the remainder of the letter. The remainder of the letter is the explanation of the need for the bill and it is vital that this information reach congressional offices intact.
Please share this with your friends, family, co-workers, or anyone you know who is struggling with chronic pain or opioids. Ask them to take action, too. The voices of the pain and headache disorders community need to ring loudly in D.C. and you really can make a difference.
Despite treatment guidelines recommending the use of oxygen for the acute therapy of cluster headache, oxygen remains underutilized. A recent study looking at the cost of oxygen for cluster headache found the reason for its lack of use may be because of poor physician awareness of the treatment, as well as the lack of understanding for how to write and fill a prescription for high-flow oxygen. Continue Reading
One of the most common reasons for an emergency department visit is pain. Despite its prevalence in this setting, it is not always managed well. A recent Australian study looked to learn more about the effectiveness of a widely used method of pain relief, acupuncture, in the emergency department setting. Continue Reading
An experimental migraine drug is showing impressive results for individuals with episodic and chronic migraine. The subcutaneous injections of fremanezumab at monthly or quarterly intervals has shown to provide rapid and sustained relief, according to the results of two Phase 3 studies. Continue Reading
Providers using the Pediatric Pain Screening Tool (PPST) were better able to identify children with headache who are at risk for poor outcomes, according to a recent study. The study, which was published in the Journal of Pediatric Psychology, shows the tool helped providers optimize individualized therapy. Continue Reading